| 重组人生长激素治疗溃疡性结肠炎临床对照研究 |
| |
| 引用本文： | 万晶晶,徐东升,杨丙寅,马兴刚. 重组人生长激素治疗溃疡性结肠炎临床对照研究[J]. 中华结直肠疾病电子杂志, 2016, 5(6): 480-483. DOI: 10.3877/cma.j.issn.2095-3224.2016.06.005 |
| |
| 作者姓名： | 万晶晶 徐东升 杨丙寅 马兴刚 |
| |
| 作者单位： | 1. 210023 南京中医药大学研究生院；223002 淮安，徐州医学院附属淮安医院（江苏淮安市第二人民医院）消化科2. 223002 淮安，徐州医学院附属淮安医院（江苏淮安市第二人民医院）消化科 |
| |
| 基金项目： | 淮安市科技局科技计划资助项目(No.HAS2013022) |
| |
| 摘 要： | 目的研究重组人生长激素（r-hGH）在溃疡性结肠炎（ulcerative colitis，UC）治疗中的作用。 方法选取2011至2016年徐州医学院附属淮安医院溃疡性结肠炎患者55例，随机分组为研究组（30例）、对照组（25例），两组患者在年龄、职业、病程、肠镜下病变范围均有可比性，Mayo评分差异无统计学意义（t值=0.163，P=0.871）。两组患者均进行基础治疗共14 d，研究者则加用重组人生长激素4 iu每天一次皮下注射，共14 d，两组患者治疗前后分别作Mayo评分及检查血清肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）。 结果研究组治疗前后Mayo评分改善（t值=15.425，P<0.001）、TNF–α下降（t值=7.080，P<0.001）差异均有显著性统计学意义，而IL-1β变化差异无显著性统计学意义（t值=0.402，P=0.691）。对照组治疗前后Mayo评分改善差异有显著性统计学意义（t值=9.165，P<0.001），TNF-α（t值=1.472，P=0.154）、IL-1β（t值=0.941，P=0.356）比较差异无显著性统计学意义。 结论重组人生长激素可以有效降低溃疡性结肠炎患者血清TNF-α水平，促进溃疡性结肠炎患者大肠粘膜的修复。
|
| 关 键 词： | 结肠 治疗 重组人生长激素 溃疡性结肠炎 对照研究 |
| 收稿时间： | 2016-09-13 |
Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis |
| |
| Jingjing Wan,Dongsheng Xu,Bingyin Yang,Xinggang Ma. Clinical control study of recombinant human growth hormone in the treatment of ulcerative colitis[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2016, 5(6): 480-483. DOI: 10.3877/cma.j.issn.2095-3224.2016.06.005 |
| |
| Authors: | Jingjing Wan Dongsheng Xu Bingyin Yang Xinggang Ma |
| |
| Affiliation: | 1. Graduated School of Nanjing University of Chinese Medicine, Nanjing 210023, China; Department of Gastroenterology, Hospital of Huai′an Affiliated to Xuzhou Medical College (Second People′s Hospital of Huai′an) , Huai′an 223002, China2. Department of Gastroenterology, Hospital of Huai′an Affiliated to Xuzhou Medical College (Second People′s Hospital of Huai′an) , Huai′an 223002, China |
| |
| Abstract: | ObjectiveTo study the effect of recombinant human growth hormone (r-hGH) in the treatment of ulcerative colitis. MethodsFifty-five patients with ulcerative colitis were collected from 2011 to 2016 in Second People′s Hospital of Huai′an, and were randomly grouped into research group (30 cases) and control group (25 cases). Two groups of patients are comparable with age, occupation, duration, colonoscopy lesions scope and Mayo score (t=0.163, P=0.163). Two groups of patients were under a total of 14 days treatment. The research group was added with subcutaneous injection of recombinant human growth hormone, 4 iu qd, 14 days. Two groups of patients were analyzed the Mayo score and serum tumor necrosis factor alpha (TNF alpha), interleukin 1 beta (IL-1 beta) before and after treatment respectively. ResultsIn research group, the Mayo score (t=15.425, P<0.001) and TNF alpha (t=7.080, P<0.001) were of highly significant statistical difference before and after treatment, there was no significant statistical difference in IL-1 beta changes (t=0.402, P=0.402). In the control group, the Mayo score was of significant statistical difference (t=9.165, P=9.165) before and after treatment, the TNF alpha beta (t=1.472, P=0.154), IL-1 (t=0.941, P=0.356) was of no significant statistical difference. ConclusionThe recombinant human growth hormone can effectively reduce the blood level of TNF alpha in ulcerative colitis patients, promoting restoration of large intestine mucosa in patients with ulcerative colitis. |
| |
| Keywords: | Colon Therapy Recombinant human growth hormone Ulcerative colitis Controlled study |
|
| 点击此处可从《中华结直肠疾病电子杂志》浏览原始摘要信息 |
|
点击此处可从《中华结直肠疾病电子杂志》下载全文 |
|
